

HETEROCYCLES, Vol. 101, No. 1, 2020, pp. 235 - 250. © 2020 The Japan Institute of Heterocyclic Chemistry
 Received, 29th May, 2019, Accepted, 16th July, 2019, Published online, 7th August, 2019
 DOI: 10.3987/COM-19-S(F)19

A MILD BISCHLER–NAPIERALSKI-TYPE CYCLIZATION OF TRICHLOROMETHYL CARBAMATES FOR THE SYNTHESIS OF β -CARBOLINONES

Seiya Hirao, Mayumi Kitamori, Tomoki Itoh, Yuusuke Chiba, and Takumi Abe*

Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido 061-0293, Japan. *E-mail: abe-t@hoku-iryu-u.ac.jp

Abstract – A straightforward synthesis of β -carbolinones by the Bischler–Napieralski-type cyclization of the corresponding trichloromethyl carbamates, which does not require acids, bases, oxidants, or transition-metals to promote the cyclization, has been achieved.

INTRODUCTION

β -Carbolinone alkaloids are a diverse group of biologically active indole alkaloids, e.g., rhetsinine,¹ strychnocarpine,² bauerine C,³ secofascaplysin A,⁴ trigonostemonines A, B,⁵ and milnamide C, F⁶ (Figure 1). For example, strychnocarpine, a simple tetrahydro- β -carbolinone alkaloid isolated from *Strychnos elaeocarpa* in 1980,^{2a} exhibits a high affinity for the peripheral type of benzodiazepine binding sites in rat brains.^{2b} These β -carbolinones have been the target of syntheses because of their intriguing structural features and interesting biological activities.






Figure 1. β -Carbolinone alkaloids

While most syntheses rely on acid-promoted Fischer indolization⁷ or transition-metal-mediated approaches,⁸ the most straightforward approach utilizes an isocyanate intermediate in a Bischler–Napieralski cyclization.⁹ However, the difficult formation of the isocyanate intermediate in strong acidic conditions needs robust substrates, which are limited to primary amines (Scheme 1a).¹⁰ Considering these cumbersome and multistep approaches, a more straightforward approach in the synthesis of β -carbolinones is highly desired.


(a) Acids-Promoted Bischler–Napieralski cyclization




(b) P_2O_5 -Promoted cyclization: Saikawa and Nakata (2014)



(c) KI-Promoted cyclization: Clayden (2018)



(d) Cyclization in the absence of promoters: This work




Scheme 1. Previously reported methods for Bischler–Napieralski cyclization

Recently, to circumvent these limitations, two pioneering reports on the mild Bischler–Napieralski-type cyclizations have been reported, including the P_2O_5 -promoted generation of a carbamoyl ion at room temperature from isopropyl benzylcarbamates developed by Saikawa, Nakata, and co-workers (Scheme 1b),¹¹ and the KI-promoted generation of a carbamoyl ion from N-chloroformylimidazolidinones through halogen exchange reported by Clayden and co-workers (Scheme 1c).¹² These reactions are notable

because (i) they allow the generation of intermediates under mild reaction conditions and (ii) the precursors are stable and easily accessible from simple starting materials. However, conversion of the precursors to lactams requires additives and can limit the use of sensitive functional groups in the substrates. These constraints restrict the utility of the mild Bischler–Napieralski cyclizations, particularly for indole alkaloid synthesis. As part of our current interest in the synthesis of indole alkaloids,¹³ we have recently determined an alternative protocol for the mild Bischler–Napieralski cyclization, which can be applicable to indole substrates. A cyclization of *N*-protected pyrano[3,2-*e*]tryptamines using triphosgene could afford β -carboline through carbamoyl ions, leading to the total synthesis of fontanesine B for the first time.¹⁴ In addition, we encountered a serendipitous isolation of the trichloromethyl carbamate derived from *N*-PMB pyrano[3,2-*e*]tryptamine. Hence, we proposed that trichloromethyl carbamates could be used as the substrate for the synthesis of a variety of lactams (Scheme 1d). To the best of our knowledge, there is no example of the cyclization of trichloromethyl carbamates to afford diverse lactams.^{15,16} In this paper, we report that trichloromethyl carbamates are sufficiently reactive for C–C bond formation to occur efficiently in the absence of acids, bases, oxidants, and transition-metals.


RESULTS AND DISCUSSION

Initially, our investigations focused on confirming the accessibility and bench-stability of the trichloromethyl carbamates.¹⁷ Stirring the amine **1a** with triphosgene (1.2 equiv) at room temperature in the presence of Et₃N as an acid scavenger afforded the trichloromethyl carbamate **2a** in 25% yield after aqueous work-up and silica gel column chromatography (Scheme 2). The trichloromethyl carbamate **2a** was stable when stored in a refrigerator as a solid for at least 6 months. With **2a** in hand, we subsequently examined the cyclization of the trichloromethyl carbamate **2a** to form the β -carbolinone **3a**.




Scheme 2. Synthesis of trichloromethyl carbamate **2a**

An evaluation of the promoters revealed that an additive was not necessary for the cyclization of **2a** (entries 1–10, Table 1). For example, heating in MeCN, without an additive, was effective in promoting cyclization, affording **3a** in 55% yield (entry 10, Table 1). Additionally, solvent effects were dramatically pronounced (entries 11–21) with DMSO being most effective in promoting the cyclization of **2a** (74% yield, entry 16).



Scheme 3. Suggested mechanism for the Bischler–Napieralski-type cyclization in DMSO


To investigate the scope of this reaction, we next attempted to prepare a wide range of trichloromethyl carbamates from their corresponding secondary amines. Although several trichloromethyl carbamates were successfully synthesized, intensive purification led to low yields (18–49%) as some of the carbamates were unstable. However, we found that the present cyclization could be applied to crude **2a** obtained from a simple aqueous work-up, affording **3a** in 76% yield (Scheme 4). Crude **2a** is sufficiently pure for use in the synthesis of **3a** without the need for intensive purification step, leading to higher yield.




Scheme 4. Alternative protocol for the Bischler–Napieralski-type cyclization via trichloromethyl carbamate

The scope of the cyclization is shown in Scheme 5. The cyclization was insensitive to substitution on the indole ring at the C5 position (**3a–c**). Various β -carbolinones with alkyl-substituted amines, such as benzyl (**3a–c**), 4-methoxybenzyl (**3d**), 2,4-dimethoxybenzyl (**3e**), and methyl-substituted benzyl (**3g** and **3h**) tryptamines, were obtained in good yield. However, decomposition of 4-cyanobenzyl tryptamine (**3f**)


was observed. While no tryptamines with electron-withdrawing groups or unprotected tryptamine (**3i-k**) were obtained, a good yield was observed when pyranoindoles were used as a substrate (**3l-3n**). Additionally, when we employed tryptophans instead of tryptamines, no product was obtained (**3o-3q**).




tryptamines: *N*-electron-donating groups




tryptamines: *N*-electron-withdrawing groups and NH



pyrano[3,2-*e*]tryptamines




tryptophans



Scheme 5. Scope and limitation of the Bischler–Napieralski-type cyclization

Unsuccessful reactions (**3i-k**, **3f**, and **3o-q**, Scheme 5) led us to rationalize that a more mild and efficient cyclization would require the identification of a suitable protecting group. We reasoned that the cyanobenzyl group might serve as a suitable protecting and activating group to enable a mild protocol for the Bischler–Napieralski-type cyclization *via* a cationic intermediate. Liu reported the effects of 2-cyanobenzyl ether for a stereospecific glycosylation reaction.²⁰ The 2-cyanobenzyl group participated in the stabilization of the oxocarbenium ion by coordinating with the cyano moiety in an intramolecular fashion. Thus, the cyclization of the 4-cyanobenzyl compound **2f** was expected to be more favorable by intermolecular coordination of the nitrile with the carbamoyl ion, which would reduce decomposition side reactions of the carbamoyl ion.

Table 2. Optimization of reaction conditions using **2f** as a substrate




entry	temp. (°C)	solvent	time (h)	yield (%) ^a
1	rt	neat	168	93
2	rt	MeCN	3	0
3	rt	1,4-dioxane	3	0
4	rt	AcOEt	3	0
5	rt	benzene	3	0
6	rt	toluene	3	0
7	rt	CHCl ₃	3	0
8	rt	DMF	3	0
9	rt	DMSO	3	0
10	rt	H ₂ O	3	0
11	rt	concd. HCl	3	trace
12	rt	MeOH	3	0
13	rt	EtOH	3	0
14	rt	<i>i</i> -PrOH	3	0
15	rt	<i>n</i> -BuOH	3	0
16	rt	<i>tert</i> -BuOH	3	0
17	rt	TFE	3	82
18	60	TFE	0.1	78
19	rt	HFIP	0.5	90
20	60	HFIP	0.1	86

^a Isolated yield.

To test this hypothesis, we prepared crude **2f** on a gram scale. Surprisingly, after 1 week at room temperature and open to air, the crude **2f** in a flask was spontaneously converted into **3f** in 93% yield (entry 1, Table 2), which supported our hypothesis and data in Scheme 5 (**3f**; decomposition).

An evaluation of solvents revealed 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) was the most effective solvent among other solvents (entries 2-20), while the reaction in MeCN (entry 2, Table 2) resulted in no cyclization (entry 2). Therefore, the details of the nitrile effects are not clear and under investigation. In contrast to the optimized reaction conditions for **2a** reported in Table 1, 2,2,2-trifluoroethanol (TFE) and HFIP exhibited better performance than DMSO in the reaction of **2f**,²¹ which indicated that this difference might be due to the performance of the stabilizer interacting with cationic intermediate in the cyclization.²²

After establishing the mild Bischler–Napieralski cyclization using 4-cyanobenzyl (4-CNBn) tryptamine in HFIP, reactions of 4-CNBn-substituted amines **7a–c** were performed (Scheme 6). Pleasingly, under reflux conditions, 4-CNBn-substituted amines with different alkyl chains were compatible and gave the corresponding lactams **9a**, **9b**, and **9c** in 51%, 59%, and 18% yields, respectively. To the best of our knowledge, this is the first time that the formation of a benzazepinone has been realized by a Bischler–Napieralski cyclization.²³



Scheme 6. Bischler–Napieralski-type cyclization of amines **7a–c**

In conclusion, we developed the Bischler–Napieralski-type cyclization of trichloromethyl carbamates in the absence of additives, giving β -carbolinones. Notably, our protocol enabled use of versatile trichloromethyl carbamates as a cyclization precursor. Furthermore, the cyclization also proceeded in HFIP at room temperature by the use of the 4-cyanobenzyl group as both protecting and activating groups. Further applications along these lines and the development of other activating groups are underway in our group.

EXPERIMENTAL

Melting points were recorded with a Yamato MP21 and are uncorrected. IR spectra were measured with a Shimadzu IRAffinity-1 spectrometer and absorbance bands are reported in wavenumbers (cm^{-1}). The NMR experiments were performed with a JEOL JNM-ECA500 (500 MHz) spectrometer. Chemical shifts in ^1H - and ^{13}C -NMR are expressed in ppm (δ). All ^{13}C NMR spectra were determined with complete proton decoupling. Column chromatography and Flash column chromatography were performed on silica gel (Silica Gel 60N, Kanto Chemical Co., Ltd.). High-resolution MS spectra were recorded with Micromass AutoSpec 3100 and JEOL JMS-T100LP mass spectrometers. All tryptamines were synthesized according to the literature.^{13h} All reagents were obtained from commercial suppliers and used without further purification.

Trichloromethyl (2-(1*H*-indol-3-yl)ethyl)(benzyl)carbamate (2a).

Triphosgene (712 mg, 2.4 mmol, 1.2 equiv) was added to a mixture of **1a** (500 mg, 2 mmol) and Et_3N (1.4 mL, 10 mmol) in MeCN (20 mL) at room temperature and the mixture was stirring for 1.5 h. After addition of H_2O (20 mL), the whole was extracted with AcOEt (3 x 50 mL), washed with brine (2 x 30 mL). The organic layer was dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (AcOEt/hexane = 1/6) to give **2a** (208 mg, 25%) as a yellow solid.

208 mg (0.51 mmol), 25%: Yellow solid: mp 200—202 °C; IR (CHCl_3): 3479, 1724, 1640 cm^{-1} ; ^1H -NMR (500 MHz, CDCl_3): δ 8.08 (br s, 1H), 7.53–7.57 (m, 1H), 7.33–7.38 (m, 4H), 7.21–7.23 (m, 2H), 7.15 (t, $J = 8.0$ Hz, 1H), 6.99, 6.98 (two s, 1H), 4.57, 4.49 (two s, 2H), 3.01–3.07 (m, 2H), 3.01–3.07 (m, 2H); ^{13}C -NMR (125 MHz, CDCl_3): δ 150.3, 149.6, 136.4, 135.9, 135.7, 128.9, 128.3, 128.2, 128.1, 127.4, 127.3, 127.1, 122.4, 122.3, 119.7, 119.6, 118.7, 118.6, 112.2, 112.0, 111.5, 111.4, 55.2, 53.1, 51.0, 50.3, 24.5, 23.2 (There are amide rotamers); HRMS (ESI): calcd for $\text{C}_{19}\text{H}_{17}\text{Cl}_3\text{N}_2\text{NaO}_2$ $[\text{M}+\text{H}]^+$ 433.0253, 435.0224, found 433.0252, 435.0221.

2-Benzyl-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-*b*]indol-1-one (3a).

A solution of compound **2a** (824 mg, 2 mmol) in DMSO (15 mL) was heated at 100 °C for 0.5 h. After addition of H_2O (20 mL), the whole was extracted with AcOEt (3 x 50 mL), washed with brine (2 x 30 mL). The organic layer was dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (AcOEt/hexane = 1/4) to give **3a** (409 mg, 74%) as a colorless powder. 409 mg (1.48 mmol), 74%: Colorless powder: mp 225—226 °C; IR (CHCl_3): 3229, 1711, 1640 cm^{-1} ; ^1H -NMR (500 MHz, CDCl_3): δ 9.47 (br s, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.43 (d, $J = 8.6$ Hz, 1H), 7.32–7.38 (m, 4H), 7.26–7.30 (m, 2H), 7.13 (t, $J = 7.5$ Hz, 1H), 4.81 (s, 2H), 3.65 (t, $J = 6.9$ Hz, 2H), 3.02 (t, $J = 6.8$ Hz, 2H); ^{13}C -NMR (125 MHz, CDCl_3): δ 161.5, 137.7, 137.5, 128.8, 128.1, 127.6, 127.0, 125.4, 125.0, 120.3, 120.2, 118.3, 112.5, 49.6, 47.5, 20.8 (two carbons are overlapped); HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$ 277.1341, found 277.1340.

General Procedure for the Synthesis of Carbolinones 3 (for 3a, 3b, 3c, 3d, 3e, 3g, and 3h).

Triphosgene (712 mg, 2.4 mmol) was added to a mixture of **1** (2 mmol) and Et₃N (1.4 mL, 10 mmol) in MeCN (20 mL) was added at room temperature and the mixture was stirring for 1.5 h. After addition of H₂O (20 mL), the whole was extracted with AcOEt (3 x 50 mL), washed with brine (2 x 30 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The crude residue was used without further purification. A solution of crude **2** in DMSO (15 mL) was heated at 100 °C for 0.5 h. After addition of H₂O (20 mL), the whole was extracted with AcOEt (3 x 50 mL), washed with brine (2 x 30 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The resultant mixture was purified by silica gel column chromatography (AcOEt/hexane = 1/4—1/6) to give **3**.

2-Benzyl-6-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one (3b).

490 mg (1.6 mmol), 80%: Colorless powder: mp 200—201 °C; IR (CHCl₃): 3227, 1640 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.69 (br s, 1H), 7.28–7.38 (m, 6H), 6.93–6.95 (m, 2H), 4.82 (s, 2H), 3.84 (s, 3H), 3.64 (t, *J* = 7.5 Hz, 2H), 2.99 (t, *J* = 6.5 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃): δ 161.7, 154.5, 137.7, 132.9, 128.8, 128.0, 127.6, 125.5, 117.8, 116.1, 113.5, 100.7, 55.9, 49.7, 47.6, 20.8 (three carbons are overlapped); HRMS (ESI): calcd for C₁₉H₁₉N₂O₂ [M+H]⁺ 307.1447, found 307.1447.

2-Benzyl-6-chloro-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one (3c).

442 mg (1.42 mmol), 71%: Colorless powder: mp 215—217 °C; IR (CHCl₃): 3460, 1641 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.90 (br s, 1H), 7.52 (d, *J* = 1.7 Hz, 1H), 7.29–7.37 (m, 6H), 7.20 (dd, *J* = 2.3, 8.6 Hz, 1H), 4.82 (s, 2H), 3.65 (t, *J* = 7.5 Hz, 2H), 2.99 (t, *J* = 7.5 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃): δ 161.5, 137.4, 136.1, 128.9, 128.2, 128.0, 127.7, 126.2, 125.9, 125.3, 119.5, 117.6, 113.9, 49.8, 47.5, 20.6 (two carbons are overlapped); HRMS (ESI): calcd for C₁₈H₁₆ClN₂O [M+H]⁺ 311.0951, 313.0922, found 311.0951, 313.0923.

2-(4-Methoxybenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one (3d).

490 mg (1.6 mmol), 80%: Colorless powder: mp 240—241 °C; IR (CHCl₃): 3219, 1640 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.88 (br s, 1H), 7.55 (d, *J* = 8.6 Hz, 1H), 7.44 (d, *J* = 8.6 Hz, 1H), 7.30 (d, *J* = 8.6 Hz, 2H), 7.25–7.28 (m, 1H), 7.12 (t, *J* = 7.5 Hz, 1H), 6.87 (d, *J* = 8.6 Hz, 2H), 4.76 (s, 2H), 3.80 (s, 3H), 3.63 (t, *J* = 7.5 Hz, 2H), 3.01 (t, *J* = 7.5 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃): δ 161.5, 159.2, 137.6, 129.8, 129.4, 127.2, 125.4, 124.9, 120.2, 120.1, 118.2, 114.2, 112.5, 55.4, 49.0, 47.3, 20.8 (two carbons are overlapped); HRMS (ESI): calcd for C₁₉H₁₈N₂NaO₂ [M+Na]⁺ 329.1266, found 329.1267.

2-(2,4-Dimethoxybenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one (3e).

463 mg (1.37 mmol), 69%: Colorless powder: mp 209—211 °C; IR (CHCl₃): 3462, 1641 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.86 (br s, 1H), 7.55 (d, *J* = 8.1 Hz, 1H), 7.43 (d, *J* = 7.5 Hz, 1H), 7.29 (d, *J* = 8.0 Hz, 1H), 7.26 (t, *J* = 8.6 Hz, 2H), 7.11 (t, *J* = 8.1 Hz, 1H), 6.48 (d, *J* = 1.7 Hz, 1H), 6.45 (dd, *J* = 2.3, 8.6 Hz, 1H), 4.78 (s, 2H), 3.83 (s, 3H), 3.80 (s, 3H), 3.69 (t, *J* = 6.9 Hz, 2H), 3.00 (t, *J* = 7.5 Hz, 2H);

^{13}C -NMR (125 MHz, CDCl_3): δ 161.7, 160.4, 158.8, 137.6, 130.5, 127.4, 125.4, 124.7, 120.1, 118.2, 118.1, 112.7, 104.3, 98.6, 55.5, 55.4, 47.7, 44.0, 20.9 (one carbon is overlapped); HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{NaO}$ $[\text{M}+\text{Na}]^+$ 359.1372, found 359.1371.

2-(2-Methylbenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one (3g).

478 mg (1.64 mmol), 82%: Colorless powder: mp 218—219 °C; IR (CHCl_3): 3462, 1641 cm^{-1} ; ^1H -NMR (500 MHz, CDCl_3): δ 9.47 (br s, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.42 (d, $J = 8.0$ Hz, 1H), 7.27–7.30 (m, 2H), 7.18–7.22 (m, 3H), 7.14 (t, $J = 7.5$ Hz, 1H), 4.81 (s, 2H), 3.62 (t, $J = 6.9$ Hz, 2H), 3.01 (t, $J = 7.5$ Hz, 2H), 2.36 (s, 3H); ^{13}C -NMR (125 MHz, CDCl_3): δ 161.4, 137.5, 136.9, 135.2, 130.7, 128.4, 127.6, 127.0, 126.2, 125.4, 125.0, 120.3, 120.2, 118.3, 112.5, 47.4, 47.0, 20.8, 19.3; HRMS (ESI): calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{NaO}$ $[\text{M}+\text{Na}]^+$ 313.1317, found 313.1321.

2-(3-Methylbenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one (3h).

482 mg (1.66 mmol), 83%: Colorless powder: mp 219—220 °C; IR (CHCl_3): 3446, 1640 cm^{-1} ; ^1H -NMR (500 MHz, CDCl_3): δ 9.77 (br s, 1H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.44 (d, $J = 7.5$ Hz, 1H), 7.27 (t, $J = 6.9$ Hz, 1H), 7.24 (t, $J = 7.5$ Hz, 1H), 7.09–7.18 (m, 4H), 4.79 (s, 2H), 3.65 (t, $J = 6.9$ Hz, 2H), 3.02 (t, $J = 6.8$ Hz, 2H), 2.33 (s, 3H); ^{13}C -NMR (125 MHz, CDCl_3): δ 161.6, 138.5, 137.6, 128.7, 128.6, 128.3, 127.1, 125.4, 125.1, 124.9, 120.3, 120.1, 118.2, 112.6, 49.6, 47.5, 21.5, 20.8 (one carbon is overlapped); HRMS (ESI): calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{NaO}$ $[\text{M}+\text{Na}]^+$ 313.1317, found 313.1314.

General Procedure for the Synthesis of Carbolinones (3l-n).

Triphosgene (356 mg, 1.2 mmol) was added to a mixture of **1** (1 mmol) and Et_3N (0.7 mL, 5 mmol) in MeCN (15 mL) was added at room temperature and the mixture was stirring for 1.5 h. After addition of H_2O (15 mL), the whole was extracted with AcOEt (3 x 30 mL), washed with brine (2 x 20 mL). The organic layer was dried over MgSO_4 and concentrated *in vacuo*. The crude residue was used without further purification. A solution of crude **2** in DMSO (10 mL) was heated at 100 °C for 0.5 h. After addition of H_2O (10 mL), the whole was extracted with AcOEt (3 x 30 mL), washed with brine (2 x 20 mL). The organic layer was dried over MgSO_4 and concentrated *in vacuo*. The resultant mixture was purified by silica gel column chromatography (AcOEt/hexane = 1/4—1/6) to give **3**.

9-Benzyl-3,3-dimethyl-7,9,10,11-tetrahydropyrano[3,2-e]pyrido[3,4-b]indol-8(3H)-one (3l).

291 mg (0.81 mmol), 81%: Colorless powder: mp 254—257 °C; IR (CHCl_3): 3460, 1641 cm^{-1} ; ^1H -NMR (500 MHz, $\text{DMSO}-d_6$): δ 11.50 (br s, 1H), 7.29–7.34 (m, 4H), 7.24 (t, $J = 6.9$ Hz, 1H), 7.12 (d, $J = 8.6$ Hz, 1H), 6.75 (d, $J = 9.8$ Hz, 1H), 6.68 (d, $J = 8.6$ Hz, 1H), 5.67 (d, $J = 9.8$ Hz, 1H), 4.66 (s, 2H), 3.54 (t, $J = 6.9$ Hz, 2H), 3.08 (t, $J = 6.9$ Hz, 2H), 1.33 (s, 6H); ^{13}C -NMR (125 MHz, $\text{DMSO}-d_6$): δ 161.0, 146.6, 138.5, 133.7, 130.4, 129.1, 128.4, 128.1, 127.7, 121.4, 119.8, 116.7, 115.5, 113.3, 113.2, 75.5, 49.1, 47.6, 27.5, 22.5 (three carbons are overlapped); HRMS (ESI): calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 359.1760, found 359.1760.

9-(4-Methoxybenzyl)-3,3-dimethyl-7,9,10,11-tetrahydropyrano[3,2-*e*]pyrido[3,4-*b*]indol-8(3*H*)-one (3m).

335 mg (0.86 mmol), 86%: Colorless powder: mp 186—187 °C; IR (CHCl₃): 3462, 1638 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.42 (br s, 1H), 7.28 (d, *J* = 8.6 Hz, 2H), 7.17 (d, *J* = 9.2 Hz, 1H), 6.86 (d, *J* = 9.2 Hz, 2H), 6.80 (d, *J* = 9.2 Hz, 1H), 6.73 (d, *J* = 9.7 Hz, 1H), 5.60 (d, *J* = 9.7 Hz, 1H), 4.72 (s, 2H), 3.80 (s, 3H), 3.60 (t, *J* = 7.2 Hz, 2H), 3.14 (t, *J* = 7.5 Hz, 2H), 1.43 (s, 6H); ¹³C-NMR (125 MHz, CDCl₃): δ 161.3, 159.1, 147.1, 133.2, 130.1, 129.6, 129.4, 128.0, 121.6, 119.6, 116.9, 116.1, 114.1, 113.6, 112.5, 75.5, 55.4, 48.9, 47.1, 27.3, 22.8 (three carbons are overlapped); HRMS (ESI): calcd for C₂₄H₂₅N₂O₃ [M+H]⁺ 389.1865, found 389.1868.

9-(2,4-Dimethoxybenzyl)-3,3-dimethyl-7,9,10,11-tetrahydropyrano[3,2-*e*]pyrido[3,4-*b*]indol-8(3*H*)-one (3n).

315 mg (0.75 mmol), 75%: Colorless powder: mp 209—211 °C; IR (CHCl₃): 3460, 1719, 1687, 1638, 1614 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.86 (br s, 1H), 7.27 (d, *J* = 8.0 Hz, 1H), 7.15 (d, *J* = 9.2 Hz, 1H), 6.76 (t, *J* = 9.5 Hz, 2H), 6.47 (d, *J* = 2.3 Hz, 1H), 6.44 (dd, *J* = 2.3, 8.6 Hz, 1H), 5.60 (d, *J* = 9.7 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.79 (s, 3H), 3.67 (t, *J* = 7.5 Hz, 2H), 3.14 (t, *J* = 6.9 Hz, 2H), 1.43 (s, 6H); ¹³C-NMR (125 MHz, CDCl₃): δ 161.6, 160.4, 158.7, 147.0, 133.4, 130.4, 129.9, 128.3, 121.6, 119.7, 118.1, 116.8, 115.8, 113.4, 112.7, 104.3, 98.6, 75.2, 55.5, 47.5, 44.0, 27.4, 22.9 (two carbons are overlapped); HRMS (ESI): calcd for C₂₅H₂₇N₂O₄ [M+H]⁺ 419.1971, found 419.1973.

2-(4-Cyanobenzyl)-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-*b*]indol-1-one (3f) (Table 2).

Triphosgene (712 mg, 2.4 mmol) was added to a mixture of **1f** (551 mg, 2 mmol) and Et₃N (1.4 mL, 10 mmol) in MeCN (20 mL) was added at room temperature and the mixture was stirring for 1.5 h. After addition of H₂O (20 mL), the whole was extracted with AcOEt (3 x 50 mL), washed with brine (2 x 30 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The crude residue was used without further purification. A solution of the crude **2f** in HFIP (5 mL) was stirred at room temperature for 0.5 h. The resultant mixture was purified by silica gel column chromatography (AcOEt/hexane = 3/1—5/1) to give **3f** (541 mg, 90%) as colorless powder.

541 mg (1.79 mmol), 90%: Colorless powder: mp 273—274 °C; IR (CHCl₃): 3199, 1647 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 11.65 (br s, 1H), 7.79 (d, *J* = 8.5 Hz, 2H), 7.55 (d, *J* = 8.1 Hz, 1H), 7.49 (d, *J* = 8.6 Hz, 2H), 7.37 (d, *J* = 8.6 Hz, 1H), 7.19 (t, *J* = 8.0 Hz, 1H), 7.02 (t, *J* = 6.9 Hz, 1H), 4.76 (s, 2H), 3.61 (t, *J* = 7.5 Hz, 2H), 2.98 (t, *J* = 7.5 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃): δ 161.3, 144.6, 138.0, 133.0, 128.9, 127.2, 125.3, 124.8, 120.7, 120.1, 119.4, 118.4, 113.1, 110.4, 49.3, 48.3, 20.7 (two carbons are overlapped); HRMS (ESI): calcd for C₁₉H₁₆N₃O [M+H]⁺ 302.1293, found 302.1297.

General Procedure for the Synthesis of Carbolinones 9 (Scheme 6).

Triphosgene (712 mg, 2.4 mmol) was added to a mixture of **7** (2 mmol) and Et₃N (1.4 mL, 10 mmol) in

MeCN (20 mL) was added at room temperature and the mixture was stirring for 1.5 h. After addition of H₂O (20 mL), the whole was extracted with AcOEt (3 x 50 mL), washed with brine (2 x 30 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The crude residue was used without further purification. A solution of the crude **8** in HFIP (5 mL) was stirred under reflux. The resultant mixture was purified by silica gel column chromatography (AcOEt/hexane = 1/4) to give **9**.

2-(4-Methylbenzyl)isoindolin-1-one (9a).

254 mg (1.02 mmol), 51%: Colorless powder: mp 136—138 °C; IR (CHCl₃): 2231, 1686 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 7.90 (d, *J* = 7.5 Hz, 1H), 7.62 (d, *J* = 8.0 Hz, 2H), 7.50 (dt, *J* = 1.1, 7.5 Hz, 1H), 7.49 (t, *J* = 7.5 Hz, 1H), 7.40-7.42 (m, 1H), 7.40 (d, *J* = 8.1 Hz, 2H), 4.86 (s, 2H), 4.30 (s, 2H); ¹³C-NMR (125 MHz, CDCl₃): δ 168.8, 142.6, 141.1, 132.8, 132.2, 131.9, 128.7, 128.4, 124.2, 123.0, 118.6, 111.8, 49.7, 46.2 (two carbons are overlapped); HRMS (ESI): calcd for C₁₆H₁₂N₂NaO [M+Na]⁺ 271.0847, found 271.0848.

2-(4-Methylbenzyl)-3,4-dihydroisoquinolin-1(2H)-one (9b).

310 mg (1.18 mmol), 59%: Colorless powder: mp 79—82 °C; IR (CHCl₃): 2232, 1708, 1647, 1609 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 8.11 (d, *J* = 8.0 Hz, 1H), 7.61 (d, *J* = 8.6 Hz, 2H), 7.42-7.44 (m, 3H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.17 (d, *J* = 7.5 Hz, 1H), 4.82 (s, 2H), 3.50 (t, *J* = 6.9 Hz, 2H), 2.97 (t, *J* = 6.9 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃): δ 164.9, 143.2, 138.1, 132.6, 132.2, 129.0, 128.6, 128.5, 127.3, 127.2, 118.8, 111.5, 50.6, 46.1, 28.2 (two carbons are overlapped); HRMS (ESI): calcd for C₁₇H₁₄N₂NaO [M+Na]⁺ 285.1004, found 285.1000.

2-(4-Methylbenzyl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one (9c).

100 mg (0.36 mmol), 18%: Colorless powder: mp 109—111 °C; IR (CHCl₃): 2232, 1632 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 7.71 (dd, *J* = 1.7, 7.5 Hz, 2H), 7.63 (d, *J* = 8.6 Hz, 1H), 7.47 (d, *J* = 8.1 Hz, 2H), 7.38 (td, *J* = 1.7, 7.5 Hz, 1H), 7.33 (dt, *J* = 1.2, 7.4 Hz, 1H), 7.13 (d, *J* = 6.9 Hz, 1H), 4.82 (s, 2H), 3.19 (t, *J* = 6.3 Hz, 2H), 2.75 (t, *J* = 6.9 Hz, 2H), 1.87 (q, *J* = 6.9 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃): δ 171.7, 143.8, 137.3, 135.5, 132.6, 131.3, 128.9, 128.8, 128.5, 127.2, 118.8, 111.6, 50.4, 46.3, 30.3, 29.3 (two carbons are overlapped); HRMS (ESI): calcd for C₁₈H₁₆N₂NaO [M+Na]⁺ 299.1160, found 299.1158.

ACKNOWLEDGEMENTS

This work was financially supported by JSPS (KAKENHI Grant Number 16K18849 for T.A.) as a Grant-in-Aid for Young Scientists (B).

REFERENCES AND NOTES


1. M. Yamazaki and T. Kawana, [YAKUGAKU ZASSHI, 1967, 87, 608](#)
2. (a) W. Rolfsen, A. M. Bresky, M. Andersson, J. Stroembom, N. E. Anden, and M.

- Grabowska-Anden, *Acta Pharm. Suec.*, 1980, **17**, 333; (b) J. Strembom, R. Jokela, V. Saano, and W. Rolfsen, *Eur. J. Pharmacol.*, 1992, **214**, 165.
3. L. K. Larsen, R. E. Moore, and G. M. L. Patterson, *J. Nat. Prod.*, 1994, **57**, 419.
 4. N. L. Seagraves, S. J. Robinson, D. Garcia, S. A. Said, X. Fu, F. J. Schmitz, H. Pietraszewicz, F. A. Valeriote, and P. Crews, *J. Nat. Prod.*, 2004, **67**, 783.
 5. X.-J. Hu, Y.-T. Di, Y.-H. Wang, L.-Y. Kong, S. Gao, C.-S. Li, H.-Y. Liu, H.-P. He, J. Ding, H. Xie, and X.-J. Hao, *Planta Med.*, 2009, **75**, 1157.
 6. R. N. Sonnenschein, J. J. Farias, K. Tenney, S. L. Mooberry, E. Lobkovsky, J. Clardy, and P. Crews, *Org. Lett.*, 2004, **6**, 779.
 7. (a) L. N. Yakhontov, M. Y. Uritskaya, O. S. Anisimova, T. Y. Filipenko, K. F. Turchin, E. M. Peresleni, and Y. N. Sheinker, *Chem. Heterocycl. Compd.*, 1975, **11**, 1270; (b) C. Herdeis and A. Dimmerling, *Heterocycles*, 1984, **22**, 2277; (c) R. Jokela and M. Lounasmaa, *Tetrahedron*, 1987, **43**, 6001; (d) T. J. Hagen, K. Narayanan, J. Names, and J. M. Cook, *J. Org. Chem.*, 1989, **54**, 2170; (e) Y. Lingam, D. M. Rao, D. R. Bhowmik, and A. Islam, *Synth. Commun.*, 2007, **37**, 4313; (f) A. Nakayama, N. Kogure, M. Kitagima, and H. Takayama, *Heterocycles*, 2008, **76**, 861; (g) G. Lin, Y. Wang, Q. Zhou, W. Tang, J. Wang, and T. Lu, *Molecules*, 2010, **15**, 5680; (h) G. Dong, S. Wang, Z. Miao, J. Yao, Y. Zhang, Z. Guo, W. Zhang, and C. Sheng, *J. Med. Chem.*, 2012, **55**, 7593; (i) C. Zheng, Y. Fang, W. Tong, G. Li, H. Wu, W. Zhou, Q. Lin, F. Yang, Z. Yang, P. Wang, Y. Peng, X. Pang, Z. Yi, J. Luo, M. Liu, and Y. Chen, *J. Med. Chem.*, 2014, **57**, 600; (j) C. M. Roggero, J. M. Giulietti, and S. P. Mulcahy, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 3549; (k) O. I. Shmatova, N. E. Shevchenko, and V. G. Nenajdenko, *Eur. J. Org. Chem.*, 2015, **2015**, 6479; (l) Y. Zhu, L.-D. Shao, Z.-T. Deng, Y. Bao, X. Shi, and Q.-S. Zhao, *J. Org. Chem.*, 2018, **83**, 10166.
 8. (a) J. Vicente, I. Saura-Llamas, and J.-A. García-López, *Organometallics*, 2009, **28**, 448; (b) B. Haffemayer, M. Gulias, and M. J. Gaunt, *Chem. Sci.*, 2011, **2**, 312; (c) Y. Higuchi, T. Mita, and Y. Sato, *Org. Lett.*, 2017, **19**, 2710; (d) H. Han, S.-D. Yang, and J.-B. Xia, *J. Org. Chem.*, 2019, **84**, 3357.
 9. (a) W. M. Whaley and T. R. Govindachari, *Org. React.*, 1951, **6**, 74; (b) M. Chrzanowska, A. Grajewska, and M. D. Rozwadowska, *Chem. Rev.*, 2016, **116**, 12369.
 10. (a) M. Decker, *Eur. J. Med. Chem.*, 2005, **40**, 305; (b) K. C. Nicolaou, J. L. Kiappes, W. Tian, V. B. Gondi, and J. Becker, *Org. Lett.*, 2011, **13**, 3924; (c) M. J. Thompson, J. C. Louth, S. M. Little, M. P. Jackson, Y. Boursereau, B. Chen, and I. Coldham, *ChemMedChem*, 2012, **7**, 578; (d) W. P. Unworth, C. Kitsiou, and R. J. K. Taylor, *Org. Lett.*, 2013, **15**, 3302; (e) J. Zhang, S. Da, X. Feng, X. Chen, J. Jiang, and Y. Li, *Chin. J. Chem.*, 2013, **31**, 123.
 11. (a) S. Adachi, K. Watanabe, Y. Iwata, S. Kameda, Y. Miyaoka, M. Onozuka, R. Mitsui, Y. Saikawa,

- and M. Nakata, *Angew. Chem. Int. Ed.*, 2013, **52**, 2087; (b) S. Adachi, M. Onozuka, Y. Yoshida, M. Ide, Y. Saikawa, and M. Nakata, *Org. Lett.*, 2014, **16**, 358.
12. (a) M. M. Amer, A. C. Carrasco, D. J. Leonard, J. W. Ward, and J. Clayden, *Org. Lett.*, 2018, **20**, 7977; (b) H. Abas, M. M. Amer, O. Olaizola, and J. Clayden, *Org. Lett.*, 2019, **21**, 1908.
13. (a) T. Abe, T. Ikeda, R. Yanada, and M. Ishikura, *Org. Lett.*, 2011, **13**, 3356; (b) T. Abe, T. Ikeda, T. Choshi, S. Hibino, N. Hatae, E. Toyota, and M. Ishikura, *Eur. J. Org. Chem.*, 2012, **2012**, 5018; (c) T. Abe, H. Komatsu, T. Ikeda, N. Hatae, E. Toyota, and M. Ishikura, *Heterocycles*, 2012, **86**, 505; (d) T. Abe, T. Ikeda, R. Yanada, and M. Ishikura, *Org. Lett.*, 2013, **15**, 3622; (e) T. Abe, T. Itoh, T. Choshi, S. Hibino, and M. Ishikura, *Tetrahedron Lett.*, 2014, **55**, 5268; (f) T. Itoh, T. Abe, T. Choshi, T. Nishiyama, R. Yanada, and M. Ishikura, *Eur. J. Org. Chem.*, 2016, **2016**, 2290; (g) T. Abe, T. Haruyama, and K. Yamada, *Synthesis*, 2017, **49**, 4141; (h) T. Abe and K. Yamada, *Org. Lett.*, 2016, **18**, 6504; (i) T. Abe and K. Yamada, *J. Nat. Prod.*, 2017, **80**, 241; (j) T. Abe, T. Suzuki, M. Anada, S. Matsunaga, and K. Yamada, *Org. Lett.*, 2017, **19**, 4275; (k) T. Abe and M. Terasaki, *Helv. Chim. Acta*, 2018, **101**, e1700284; (l) T. Abe and K. Yamada, *Org. Lett.*, 2018, **20**, 1469; (m) T. Abe, *Heterocycles*, 2018, **96**, 490; (n) T. Abe, T. Morita, and K. Yamada, *Heterocycles*, 2018, **97**, 141; (o) T. Abe, S. Satake, and K. Yamada, *Heterocycles*, 2019, **99**, 379; (p) T. Abe, S. Aoyama, M. Ohmura, M. Taniguchi, and K. Yamada, *Org. Lett.*, 2019, **21**, 3367.
14. T. Itoh, Y. Chiba, S. Kawaguchi, Y. Koitaya, Y. Yoneta, K. Yamada, and T. Abe, *RSC Adv.*, 2019, **9**, 10420.
15. For examples of triphosgene mediated halogenations, see: (a) C. E. Ayala, A. Villalpando, A. L. Nguyen, G. T. McCandless, and R. Kartika, *Org. Lett.*, 2012, **14**, 3676; (b) A. Villalpando, C. E. Ayala, C. B. Watson, and R. Kartika, *J. Org. Chem.*, 2013, **78**, 3989; (c) M. A. Sapotra, L. Ngo, and R. Kartika, *J. Org. Chem.*, 2015, **80**, 8815; (d) A. Villalpando, M. A. Sapotra, T. H. Tugwell, and R. Kartika, *Chem. Commun.*, 2015, **51**, 15075; (e) A. H. Cleveland, F. R. Fronczek, and R. Kartika, *J. Org. Chem.*, 2018, **83**, 3367.
16. For selected examples of coupling reactions using triphosgene, see: (a) A. Armstrong, I. D. Edmonds, and M. E. Swarbrick, *Tetrahedron Lett.*, 2003, **44**, 5335; (b) O. P. Gulin, F. Rabanal, and E. Giralt, *Org. Lett.*, 2006, **8**, 5385; (c) W. Su, S. J. Gray, R. Dondi, and G. A. Burley, *Org. Lett.*, 2009, **11**, 3910; (d) S. T. Le Quement, T. Flagstad, R. J. T. Mikkelsen, M. R. Hansen, M. C. Givskov, and T. E. Nielsen, *Org. Lett.*, 2012, **14**, 640; (e) Z. Wu, T. Hu, L. He, and B. Gong, *Org. Lett.*, 2012, **14**, 2504; (f) L. Fang, G. Yao, Z. Pan, C. Wu, H.-S. Wang, G. A. Burley, and W. Su, *Org. Lett.*, 2015, **17**, 158; (g) K. Leczycka-Wilk, K. Dabrowa, P. Cmoch, and S. Jarosz, *Org. Lett.*, 2017, **19**, 4596; (h) S. E. Varjosaari, P. Suating, and M. J. Adler, *Synthesis*, 2016, **48**, 43.
17. Trichloromethyl carbamate easily decomposes to give the corresponding carbamic acid, see: A. C.

Sosa, R. Conway, R. T. Williamson, J. P. Suchy, W. Edwards, and T. Cleary, *Org. Process Res. Dev.*, 2011, **15**, 1458.

18. For examples of Swern oxidation using phosgene-DMSO system, see: (a) S. Takano, K. Inomata, S. Tomita, M. Yanase, K. Samizu, and K. Ogasawara, *Tetrahedron Lett.*, 1988, **29**, 6619; (b) C. Palomo, F. P. Cossio, J. M. Ontoria, and J. M. Odorizola, *J. Org. Chem.*, 1991, **56**, 5948; (c) G. Mehta and H. M. Shinde, *J. Org. Chem.*, 2012, **77**, 8056.
19. A. J. Mancuso, S. Huang, and D. Swern, *J. Org. Chem.*, 1978, **43**, 2480.
20. K. L. M. Hoang and X.-W. Liu, *Nat. Commun.*, 2014, **5**, 5051.
21. When the reaction of **2a** without a CN group using HFIP, a trace amount of **3a** could be obtained (eq 1). These results suggest that the combination use of the trichloromethyl carbamate bearing the 4-cyanobenzyl group and HFIP is necessary for operating this transformation under the mild conditions.



22. Selected examples of the improvement of the yield by using TFE or HFIP in the reaction through cationic intermediates, see: (a) A. G. Myers and J. K. Babary, *Org. Lett.*, 2001, **3**, 425; (b) A. Saito, J. Numaguchi, and Y. Hanzawa, *Tetrahedron Lett.*, 2007, **48**, 835; (c) M. Harmata, C. Huang, P. Rooshenas, and P. R. Schreiner, *Angew. Chem. Int. Ed.*, 2008, **47**, 8696; (d) C. S. Jeffrey, K. L. Barnes, J. A. Eickhoff, and C. R. Carson, *J. Am. Chem. Soc.*, 2011, **133**, 7688; (e) L.-N. Wang, S.-L. Shen, and J. Qu, *RSC Adv.*, 2014, **4**, 30733.
23. For an example of an azepinoindole formation by the Bischler–Napieralski cyclization, see: T. Buyck, Q. Wang, and J. Zhu, *Org. Lett.*, 2012, **14**, 1338.